Autoanticuerpos: una manifestación de los eventos adversos inmunológicos de la inmunoterapia en cáncer

Van der Vlist, 2016, Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?, Nat Rev Rheumatol., 12, 593, 10.1038/nrrheum.2016.131 Friedman, 2016, Treatment of the immune-related adverse effects of immune checkpoint inhibitors, JAMA Oncol., 2, 1346, 10.1001/jamaoncol.2016.1051 Nielen, 2004, Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors, Arthritis Rheum., 50, 380, 10.1002/art.20018 Blank, 2016, Cancer immunology. The “cancer immunogram” visualizing the state of cancer-immune system interactions may spur personalized therapy, Science, 352, 658, 10.1126/science.aaf2834 Belkhir, 2017, Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment, Ann Rheum Dis., 76, 1747, 10.1136/annrheumdis-2017-211216 Cappelli, 2017, Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab, Ann Rheum Dis., 76, 43, 10.1136/annrheumdis-2016-209595 Brahmer, 2018, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol., 36, 1714, 10.1200/JCO.2017.77.6385 Urrego-Callejas, 2019, Cutaneous and pulmonary sarcoid-like reaction induced by nivolumab, J Clin Rheumatol. Wei, 2018, Fundamental mechanisms of immune checkpoint blockade therapy, Cancer Discov., 8, 1069, 10.1158/2159-8290.CD-18-0367 Calabrese, 2017, Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity, RMD Open., 3, e000412, 10.1136/rmdopen-2016-000412 Xu, 2018, Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis, BMJ., 363, k4226, 10.1136/bmj.k4226 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med., 366, 2443, 10.1056/NEJMoa1200690 Ramos-Casals, 2020, Immune-related adverse events of checkpoint inhibitors, Nat Rev Dis Primers., 6, 38, 10.1038/s41572-020-0160-6 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med., 371, 2189, 10.1056/NEJMoa1406498 Rivera, 2017, Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer, JAMA Dermatology, 153, 1162, 10.1001/jamadermatol.2017.2106